Cargando…

Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma(1)

BACKGROUND: Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limited. Dose escalation for other TKIs has been shown to afford added disease contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Akanksha, Elias, Roy, Christie, Alana, Williams, Noelle S., Pedrosa, Ivan, Bjarnason, Georg A., Brugarolas, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894028/ https://www.ncbi.nlm.nih.gov/pubmed/36743424 http://dx.doi.org/10.3233/KCA-210117

Ejemplares similares

Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma
por: Sharma, Akanksha, et al.
Publicado: (2023)

Managing Cardiac Resynchronization Therapy Nonresponse: Conventional and Unconventional Techniques
por: Trohman, Richard G., et al.
Publicado: (2018)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Extended-Interval Gentamicin Dosing for Pulmonic Tularemia
por: Dietrich, Tyson, et al.
Publicado: (2019)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma
por: Patel, Viral, et al.
Publicado: (2020)

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
por: Gan, Chun Loo, et al.
Publicado: (2021)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
por: Uche, An, et al.
Publicado: (2019)

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
por: Boustany, Johnny, et al.
Publicado: (2020)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer
por: Kumar, Shreya, et al.
Publicado: (2023)

A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
por: Kessler, Elizabeth R., et al.
Publicado: (2023)

Rare metastatic sites of renal cell carcinoma: a case series
por: Singla, Anurag, et al.
Publicado: (2022)

Unconventional quantum criticality in a non-Hermitian extended Kitaev chain
por: Rahul, S., et al.
Publicado: (2023)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
por: Wadsley, Jonathan, et al.
Publicado: (2023)

Determinants of renal cell carcinoma invasion and metastatic competence
por: Kim, Kangsan, et al.
Publicado: (2021)

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
por: Lemke, Emily A., et al.
Publicado: (2019)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022)

Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type
por: Cai, Qi, et al.
Publicado: (2019)

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report
por: Blum, Veronika, et al.
Publicado: (2022)

Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy
por: Sidlik Muskatel, Rakefet, et al.
Publicado: (2022)

From the Breast to the Bowel: An Unconventional Metastatic Presentation
por: Gangireddy, Mounika, et al.
Publicado: (2019)

Extended salvage surgery after high-dose chemoradiation therapy for tumors in the cervico-thoracic junction with invasion of the chest wall and the spine: a case series
por: Wiendieck, Kurt, et al.
Publicado: (2022)

Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases
por: Read, William L., et al.
Publicado: (2017)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
por: Hayashida, Michikata, et al.
Publicado: (2023)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Metastatic Renal Cell Carcinoma to the Testis: A Clinicopathologic Analysis of Five Cases
por: Wang, Gang, et al.
Publicado: (2020)

Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone
por: Yu, Kai-Jie, et al.
Publicado: (2017)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hrd0reh4b0dd57j9pmd23n0s1g